Abstract

PURPOSE OF REVIEW

The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to guide individualized therapeutic decisions. This review summarizes new findings related to lupus nephritis over the last 18 months and discusses clinical needs that should be considered to advance trials of mechanism-based therapeutic strategies.

RECENT FINDINGS

Collaborative teams are addressing how to improve disease definitions and are developing predictive models for disease onset, disease response and risk of flare in individual patients. More attention is being paid to clinical trial design. Advanced technologic approaches are allowing the analysis of small amounts of human tissue and urine in unprecedented detail so as to discover new pathogenic mechanisms and identify disease biomarkers. Novel therapies continue to be tested in disease models and include new strategies to protect renal tissue from cell damage and fibrosis.

SUMMARY

The collaborative efforts of patients, clinical and translational researchers, the pharmaceutical industry and funding sources are needed to advance therapies for lupus nephritis. Specialized clinical centers can then deliver optimal and more personalized patient care that will improve patient outcomes.

MeSH

Lupus Nephritis, Rheumatic Diseases, Therapeutics, Arthritis, Tissues

Cited by

• [Clinicopathological features of children with lupus nephritis with positive antineutrophil cytoplasmic antibody]. Zhongguo Dang Dai Er Ke Za Zhi, 2021
• Cordyceps cicadae ameliorates inflammatory responses, oxidative stress, and fibrosis by targeting the PI3K/mTOR-mediated autophagy pathway in the renal of MRL/lpr mice. Immun Inflamm Dis, 2024
• The Role of Advanced Glycation End Products and Its Soluble Receptor in Kidney Diseases. Int J Mol Sci, 2022
• Application of herbal traditional Chinese medicine in the treatment of lupus nephritis. Front Pharmacol, 2022
• Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med, 2023
• Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease. Lupus Sci Med, 2022
• Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice. Front Immunol, 2023
• Prioritization of Diagnostic and Prognostic Biomarkers for Lupus Nephritis Based on Integrated Bioinformatics Analyses. Front Bioeng Biotechnol, 2021
• Interleukin-12 exacerbates symptoms in an MRL/MpJ-Faslpr mouse model of systemic lupus erythematosus. Exp Ther Med, 2021
• Revisited Cyclophosphamide in the Treatment of Lupus Nephritis. Biomed Res Int, 2022
• Impact of gut microbiota in chronic kidney disease: natural polyphenols as beneficial regulators. Ren Fail, 2025
• Silent Lupus Nephritis: Renal Histopathological Profile and Early Detection with Urinary Monocyte Chemotactic Protein 1. Open Access Rheumatol, 2022
• Renal interferon-inducible protein 16 expression is associated with disease activity and prognosis in lupus nephritis. Arthritis Res Ther, 2023
• Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide. Clin Rheumatol, 2023
• Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience. J Clin Med, 2022
• Reduced Renal CSE/CBS/H2S Contributes to the Progress of Lupus Nephritis. Biology (Basel), 2023